Drugs / SSK12@Lip@GSH
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06446180 | Jun → Aug 2024 | mucositis | The General Hospital of Western Theater Command | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSK12@Lip@GSH | “the investigators evaluated the treatment outcome of SSK12@Lip@GSH on RIOM mice .” NCT06446180 ↗ |
| Known as | K12@Lip@GSH | “the investigators designed a new oral probiotic K12@Lip@GSH that SSK12 is encapsulated in liposomes(Lip) to enhance its stability and free radical scavenging ability” NCT06446180 ↗ |
| Modality | Other / unclassified | “the investigators designed a new oral probiotic K12@Lip@GSH” NCT06446180 ↗ |